TAK-285
| Code | Size | Price |
|---|
| SYN-1153-M100 | 100 mg | Enquire |
Quantity:
| SYN-1153-M050 | 50 mg | Enquire |
Quantity:
| SYN-1153-M001 | 1 mg | £203.00 |
Quantity:
| SYN-1153-M005 | 5 mg | £315.00 |
Quantity:
| SYN-1153-M010 | 10 mg | £543.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
TAK285
Appearance:
Solid.
CAS:
871026-44-7
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C26H25ClF3N5O3/c1-25(2,37)14-22(36)31-9-11-35-10-8-20-23(35)24(33-15-32-20)34-17-6-7-21(19(27)13-17)38-18-5-3-4-16(12-18)26(28,29)30/h3-8,10,12-13,15,37H,9,11,14H2,1-2H3,(H,31,36)(H,32,33,34)
InChiKey:
ZYQXEVJIFYIBHZ-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 871026-44-7. Formula: C26H25ClF3N5O3. MW: 548. TAK-285 is a novel investigational dual HER2/EGFR inhibitor with IC(50) values of 17 and 23nM, respectively.
Molecular Formula:
C26H25ClF3N5O3
Molecular Weight:
548
Package Type:
Plastic Vial
Product Description:
TAK-285 is a novel investigational dual HER2/EGFR inhibitor with IC(50) values of 17 and 23nM, respectively.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold: T. Ishikawa, et al.; J. Med. Chem. 54, 8030 (2011)
Related Products
| Product Name | Product Code | Supplier | BMS-599626 | SYN-1142 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|